Synthesis, physicochemical and pharmacological characterizations of a tetra-[methylimidazolium] dihydrogen decavanadate, inhibiting the IGR39 human melanoma cells development

被引:1
作者
Aissa, Taissir [1 ]
Aissaoui-Zid, Dorra [2 ]
Moslah, Wassim [2 ]
Khamessi, Oussema [3 ,4 ]
Ksiksi, Regaya [1 ,5 ]
Oltermann, Maike [6 ]
Ruck, Michael [6 ]
Zid, Mohamed Faouzi [1 ]
Abid, Najet Srairi- [2 ]
机构
[1] Univ Tunis El Manar, Fac Sci Tunis, Lab Mat Crystal Chem & Appl Thermodynam, LR15ES01, El Manar II, Tunis 2092, Tunisia
[2] Univ Tunis El Manar, Pasteur Inst Tunis, Lab Biomol Venoms & Theranost Applicat LR20IPT01, Tunis, Tunisia
[3] Univ Tunis El Manar, Pasteur Inst Tunis, Lab Bioinformat Biomath & Biostat BIMS, Tunis, Tunisia
[4] Univ Manouba, Higher Inst Biotechnol Sidi Thabet ISBST, Ariana 2020, Tunisia
[5] Carthage Univ, Higher Inst Preparatory Studies Biol & Geol ISEP B, 49 Ave August 13 Choutrana,II, Soukra 2036, Tunisia
[6] Tech Univ Dresden, Dept Chem & Food Chem, D-01062 Dresden, Germany
关键词
Polyoxidovanadates; Decavanadate; Metallodrugs; Melanoma; IGR39; cells; Anticancer activity; MALIGNANT-MELANOMA; OPTICAL-PROPERTIES; CRYSTAL-STRUCTURE; DIAGNOSIS; PROGRESSION; APOPTOSIS; THERAPY; CATIONS; DRUGS; GPR40;
D O I
10.1016/j.jinorgbio.2024.112672
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Melanoma is a skin cancer that arises from melanocytes and can spread quickly to the other organs of the body, if not treated early. Generally, melanoma shows an inherent resistance to conventional therapies. In this regard, new potential drugs are being developed as possible treatments for melanoma. In this paper, we report the synthesis of a new decavanadate compound with organic molecules for a potential therapeutic application. The tetra-[methylimidazolium] dihydrogen decavanadate(V) salt (C4H7N2)4[H2V10O28] 4 H 7 N 2 ) 4 [H 2 V 10 O 28 ] is characterized by single- crystal X-ray diffraction, by FT-IR, UV-Vis and 51 V NMR spectroscopy, as well as by thermal analysis (TGA and DSC). The compound crystallizes in the monoclinic centrosymmetric space group P 2 1 / c . Its formula unit consists of one dihydrogen decavanadate anion [H 2 V 10 O 28 ] 4- and four organic 4-methylimidazolium cations (C4H7N2)+. 4 H 7 N 2 ) + . Important intermolecular interactions are N-H & sdot;& sdot;& sdot;O and O-H & sdot;& sdot;& sdot;O hydrogen bonds and it-it stacking interactions between the organic cations, revealed by analysis of the Hirshfeld surface and its two-dimensional fingerprint plots. Interestingly, this compound inhibits the viability of IGR39 cells with IC50 50 values of 14.65 mu M and 4 mu M after 24 h and 72 h of treatment, respectively. The analysis of its effect by flow cytometry using an Annexin V-FITC/IP cell labeling, showed that (C 4 H 7 N 2 ) 4 H 2 V 10 O 28 compound induced IGR39 cell apoptosis and necrosis. Molecular docking studies performed against TNFR1 and GPR40, as putative targets, suggest that the (C4H7N2)4[H2V10O28] 4 H 7 N 2 ) 4 [H 2 V 10 O 28 ] compound may act as inhibitor of these proteins, known to be overexpressed in melanoma cells. Therefore, we could consider it as a new potential metallodrug against melanoma.
引用
收藏
页数:13
相关论文
共 88 条
[21]   Melanoma: Last call for radiotherapy [J].
Espenel, Sophie ;
Vallard, Alexis ;
Rancoule, Chloe ;
Garcia, Max-Adrien ;
Guy, Jean-Baptiste ;
Chargari, Cyrus ;
Deutsch, Eric ;
Magne, Nicolas .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 110 :13-19
[22]  
Farrugia L., 1999, J. Appl. Crystallogr., V32, P837, DOI DOI 10.1107/S0021889812029111
[23]   WinGX and ORTEP for Windows: an update [J].
Farrugia, Louis J. .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 2012, 45 :849-854
[24]   Immunotherapy in melanoma [J].
Feld, Emily ;
Mitchell, Tara C. .
IMMUNOTHERAPY, 2018, 10 (11) :987-998
[25]   The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice [J].
Ferrara, Gerardo ;
Argenziano, Giuseppe .
FRONTIERS IN ONCOLOGY, 2021, 11
[26]   Role of radiation therapy in melanomas: Systematic review and best practice in 2016 [J].
Fort, Magali ;
Guet, Saada ;
Husheng, Shan ;
Calitchi, Elie ;
Belkacemi, Yazid .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 99 :362-375
[27]   Different effects of GPR120 and GPR40 on cellular functions stimulated by 12-O-tetradecanoylphorbol-13-acetate in melanoma cells [J].
Fukushima, Kaori ;
Takahashi, Kaede ;
Fukushima, Nobuyuki ;
Honoki, Kanya ;
Tsujiuchi, Toshifumi .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 475 (01) :25-30
[28]   Systems biology of cisplatin resistance: past, present and future [J].
Galluzzi, L. ;
Vitale, I. ;
Michels, J. ;
Brenner, C. ;
Szabadkai, G. ;
Harel-Bellan, A. ;
Castedo, M. ;
Kroemer, G. .
CELL DEATH & DISEASE, 2014, 5 :e1257-e1257
[29]   Diagnosis and treatment of cutaneous melanoma: state of the art 2006 [J].
Garbe, Claus ;
Elgentler, Thomas K. .
MELANOMA RESEARCH, 2007, 17 (02) :117-127
[30]   2-Aminopyrimidinium Decavanadate: Experimental and Theoretical Characterization, Molecular Docking, and Potential Antineoplastic Activity [J].
Garcia-Garcia, Amalia ;
Noriega, Lisset ;
Melendez-Bustamante, Francisco J. ;
Castro, Maria Eugenia ;
Sanchez-Gaytan, Brenda L. ;
Choquesillo-Lazarte, Duane ;
Gonzalez-Vergara, Enrique ;
Rodriguez-Dieguez, Antonio .
INORGANICS, 2021, 9 (09)